222 related articles for article (PubMed ID: 34466299)
21. Clinical Response of Advanced Lung Adenocarcinoma with Class III BRAF G466V Missense Mutation to Dabrafenib and Trametinib: A Case Report.
Fang R; Xu S; Gong J; Liao Z
Onco Targets Ther; 2024; 17():27-31. PubMed ID: 38283732
[TBL] [Abstract][Full Text] [Related]
22. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
Dhillon S
Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
[TBL] [Abstract][Full Text] [Related]
23. An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAF
Fang R; Gong J; Liao Z
Front Oncol; 2023; 13():1220745. PubMed ID: 37546400
[TBL] [Abstract][Full Text] [Related]
24. Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma.
Wang W; Smith JL; Carlino MS; Burmeister B; Pinkham MB; Fogarty GB; Christie DRH; Estall V; Shackleton M; Clements A; Wolfe R; Thao LTP; Paton EJ; Steel V; Williams NC
Clin Transl Radiat Oncol; 2021 Sep; 30():95-99. PubMed ID: 34458597
[TBL] [Abstract][Full Text] [Related]
25. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
26. Complete response of metastatic
Lee SJ; Song SY; Kim MK; Na HG; Bae CH; Kim YD; Choi YS
World J Clin Cases; 2023 Sep; 11(27):6664-6669. PubMed ID: 37900238
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
[No Abstract] [Full Text] [Related]
28. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
Daud A; Gill J; Kamra S; Chen L; Ahuja A
J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
[TBL] [Abstract][Full Text] [Related]
29. Dabrafenib plus trametinib in patients with BRAF
Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
[TBL] [Abstract][Full Text] [Related]
30. Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.
Noeparast A; Teugels E; Giron P; Verschelden G; De Brakeleer S; Decoster L; De Grève J
Oncotarget; 2017 Sep; 8(36):60094-60108. PubMed ID: 28947956
[TBL] [Abstract][Full Text] [Related]
31. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
Lacroix JP; Wang B
J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
[TBL] [Abstract][Full Text] [Related]
32. Success of rechallenging dabrafenib and trametinib combination therapy after trametinib-induced rhabdomyolysis: a case report.
Muto Y; Ng W; Namikawa K; Takahashi A; Tsutsumida A; Nishida M; Yamazaki N
Melanoma Res; 2018 Apr; 28(2):151-154. PubMed ID: 29356791
[TBL] [Abstract][Full Text] [Related]
33. Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis.
Li J; Sasane M; Zhao J; Horton VG; Zhang P; Ricculli ML; Zhou ZY; Signorovitch J
Adv Ther; 2018 Jul; 35(7):1035-1048. PubMed ID: 29949047
[TBL] [Abstract][Full Text] [Related]
34. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
Atkinson V; Sandhu S; Hospers G; Long GV; Aglietta M; Ferrucci PF; Tulyte S; Cappellini GCA; Soriano V; Ali S; Poprach A; Cesas A; Rodriguez-Abreu D; Lau M; de Jong E; Legenne P; Stein D; King B; van Thienen JV
Melanoma Res; 2020 Jun; 30(3):261-267. PubMed ID: 31895752
[TBL] [Abstract][Full Text] [Related]
35. Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma.
Homet Moreno B; Mok S; Comin-Anduix B; Hu-Lieskovan S; Ribas A
Oncoimmunology; 2016 Jul; 5(7):e1052212. PubMed ID: 27622011
[TBL] [Abstract][Full Text] [Related]
36. Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report.
Su PL; Lin CY; Chen YL; Chen WL; Lin CC; Su WC
JTO Clin Res Rep; 2021 Aug; 2(8):100202. PubMed ID: 34590045
[TBL] [Abstract][Full Text] [Related]
37. Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation.
Qu J; Shen Q; Li Y; Kalyani FS; Liu L; Zhou J; Zhou J
Front Oncol; 2022; 12():911303. PubMed ID: 35814395
[TBL] [Abstract][Full Text] [Related]
38. Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy.
Weart TC; Miller KD; Simone CB
Cancer Manag Res; 2018; 10():647-652. PubMed ID: 29662327
[TBL] [Abstract][Full Text] [Related]
39. Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer.
Noeparast A; Giron P; De Brakeleer S; Eggermont C; De Ridder U; Teugels E; De Grève J
Oncotarget; 2018 Mar; 9(22):16110-16123. PubMed ID: 29662630
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
